Mylan to launch generic EpiPen at half the price of original
The company reduced the out-of-pocket costs of EpiPen for some patients on Thursday, but kept the list price at about $600, a move that U.S. lawmakers and Presidential candidate Hillary Clinton said was not enough. Mylan said on Monday it expected to launch the generic product “in several weeks”, an unusual move considering the branded bestseller is still patent protected and major rival treatments have failed to get regulatory clearances. “Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response,” Chief Executive Heather Bresch said Monday.